Consolidated Net Income/Loss (Quarterly)

Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.

Regeneron Pharmaceuticals, Inc. (REGN) had Consolidated Net Income/Loss of $1.46B for the most recently reported fiscal quarter, ending 2025-09-30.

Quarterly Annual

Figures for fiscal quarter ending 2025-09-30

Income Statement Financials
Revenue	$3.75B
Net Income	$1.46B
Cost of Goods Sold	$521.60M
Gross Profit	$3.23B
Operating Expenses	$2.73B
Operating Income	$1.03B
Non-Operating Income/Expense	$736.50M
Pre-Tax Income	$1.76B
Normalized Pre-Tax Income	$1.76B
Income after Taxes	$1.46B
Income from Continuous Operations	$1.46B
Consolidated Net Income/Loss	$1.46B
Normalized Income after Taxes	$1.46B
EBIT	$1.03B
EBITDA	$1.16B
Weighted-Average Shares Outstanding (Basic)	103.60M
Weighted-Average Shares Outstanding (Diluted)	107.20M
Earnings per Share (EPS) (Basic)	$14.09
Earnings per Share (EPS) (Diluted)	$13.62
Balance Sheet Financials
Current Assets	$17.98B
Property, Plant, and Equipment	$5.00B
Long-Term Assets	$22.19B
Total Assets	$40.17B
Current Liabilities	$4.43B
Long-Term Debt	$2.71B
Long-Term Liabilities	$4.79B
Total Liabilities	$9.21B
Common Equity	$30.96B
Tangible Shareholders Equity	$29.58B
Shareholders Equity	$30.96B
Common Shares Outstanding	105.30M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$3.81B
Cash Flow from Investing Activities	$-849.40M
Cash Flow from Financial Activities	$-2.94B
Beginning Cash	$2.49B
End Cash	$2.51B
Increase/Decrease in Cash	$24.10M
Stock-Based Compensation	$744.40M
Common Stock Dividends Paid	$-277.60M
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	4.06
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.08
Debt to Equity Ratio	0.09
Gross Margin	86.11%
Operating Margin	27.35%
EBIT Margin	27.35%
EBITDA Margin	--
Pre-Tax Profit Margin	46.97%
Profit Margin	38.89%
Free Cash Flow	$3.16B
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.09
Inventory Turnover	0.16
Receiveable Turnover	0.66
Days Sales in Receivables	136.33
Return on Equity	4.72%
Return on Tangible Equity	4.94%
Return on Assets	3.63%
Return on Investments	4.34%
Book Value Per Share	$294.00
Free Cash Flow per Share	$29.46
Operating Cash Flow per Share	$35.52

Data from Zacks Investment Research, Inc.